Axis Wealth Partners LLC Purchases New Shares in Pfizer Inc. (NYSE:PFE)

Axis Wealth Partners LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 10,924 shares of the biopharmaceutical company’s stock, valued at approximately $290,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the 4th quarter worth about $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer in the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the fourth quarter worth approximately $28,000. Gladius Capital Management LP boosted its stake in Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares during the last quarter. Finally, Noble Wealth Management PBC acquired a new stake in Pfizer during the 4th quarter worth $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock opened at $26.71 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $151.35 billion, a P/E ratio of 18.94, a P/E/G ratio of 0.64 and a beta of 0.61. The business’s 50-day moving average is $26.30 and its two-hundred day moving average is $27.24. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the company earned $0.10 earnings per share. The firm’s revenue was up 24.7% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 7th. Shareholders of record on Friday, January 24th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.44%. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on PFE shares. Citigroup lowered their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. UBS Group lowered their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim reissued a “buy” rating and set a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. Finally, Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.